Montelukast does not appear to increase the risk for neuropsychiatric adverse events in children and adolescents, according to a study published in JAMA Pediatrics. Montelukast is a leukotriene ...

Teva Pharmaceutical Industries Limited’s TEVA share price has dipped by 13.89%, which has investors questioning if this is ...

Kinaset Therapeutics, a clinical-stage biopharmaceutical company developing inhaled therapeutics to treat serious respiratory diseases, today announced that the United States Food and Drug ...

A small proportion of veterans who went from a metered-dose inhaler to a dry-powder inhaler had to revert to the metered-dose ...

Authenticated data presented in the Respiratory Drugs market report is based on findings of extensive primary and secondary research ...

No significant risks were seen for specific neuropsychiatric events individually or in any subgroup or sensitivity analysis, ...

Get Wall Street's Hottest Chart Every Morning "Well, I think the answer is yes. I mean it's been a long time," Yellen said. She then explained that in order to learn how to inhale she had to go ...

New research into the use of beta agonists released this week raises concerns about the animal health and welfare of feedlot cattle. The peer-reviewed article, while acknowledging “significant ...

Join MIMS now and pay nothing for the first 30 days Join GPOnline now and pay nothing for the first 30 days ...

The global short-acting beta-agonists market, crucial medications for treating asthma and COPD, is poised for substantial growth according to recent market analysis. Starting at USD 675 million in ...

Lyndra’s long-acting oral therapies, including lead investigational product oral weekly risperidone (LYN-005), are designed to deliver medication for a week or longer with a single oral dose.

As Lyndra Therapeutics works to advance long-acting oral drugs for a range of diseases, the Massachusetts-based biotech is tapping contracting juggernaut Thermo Fisher Scientific to help meet its ...